Investment in regenerative medicine


Promenade 69


Mike Moradi
Mr. Moradi is a biotechnology investor and entrepreneur. He co-founded several biopharma
and nanotech companies, including angel and venture capital funds. His most recent fund is
Hexagon, which is focused in regenerative medicine with world-leading universities and
research institutions. Sensulin, is developing a next-generation insulin for diabetes. Mike was
previously a co-founder and CEO of a pharmaceutical company targeting ocular complications of diabetes, and specialty Contract Research Organization (eyeCRO), which was #264 fastest growing private company in the 2009 Inc. 500. He co-founded Nanopolaris (now Unidym), which was acquired in 2011 by a publicly traded South Korean company for $145M USD, and NanoSource, which was acquired by DuPont in 2002, largely considered the first major acquisition in the nanotech space. Mike was a trustee for the $9B USD Oklahoma Pension Employees Retirement System (OPERS), and a member of the audit committee. He is a regular attendee of the flagship TED conference, and the World Economic Forum in Davos. He holds a degree in biochemistry from the University of Oklahoma, with additional coursework from Oxford University’s Saïd Business School, the Lee Kuan Yew School of Public Policy at the National University of Singapore, and the University of Cape Town’s Graduate School of Business. Mike was named to the World Economic Forum’s (WEF) 2017-2022 class of Young Global Leaders

Leave a Comment

BoldItalicStrikethroughOrdered listUnordered list
Attach a file you can also drag-and-drop into the text area below:
Align leftAlign centerAlign rightToggle HTML viewToggle full pageToggle lights
Drop image/file